Form 8-K - Current report:
SEC Accession No. 0001193125-25-162233
Filing Date
2025-07-22
Accepted
2025-07-22 07:31:48
Documents
14
Period of Report
2025-07-21
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d89717d8k.htm   iXBRL 8-K 27884
2 EX-99.1 d89717dex991.htm EX-99.1 11652
6 GRAPHIC g89717g0722023909518.jpg GRAPHIC 2516
  Complete submission text file 0001193125-25-162233.txt   162401

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lnth-20250721.xsd EX-101.SCH 2853
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lnth-20250721_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lnth-20250721_pre.xml EX-101.PRE 11263
16 EXTRACTED XBRL INSTANCE DOCUMENT d89717d8k_htm.xml XML 3641
Mailing Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862
Business Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862 978 671-8001
Lantheus Holdings, Inc. (Filer) CIK: 0001521036 (see all company filings)

EIN.: 352318913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36569 | Film No.: 251138686
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)